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The main function of the immune system is to protect the host against microbial pathogens and
their deleterious products. Innate defense mechanisms quickly eliminate infectious intruders or
keep them in check until highly specific adaptive responses that also give rise to immunological
memory are launched. Major histocompatibility complex (MHC)-restricted T cells are key players
of adaptive immunity. The remarkable diversity of their T cell receptors (TCRs) allows for specific
recognition of peptides derived from virtually all protein antigens (Ags) including those harbored or
even modified by the most vicious pathogens encountered over one’s lifetime. Conventional T cells
sense and respond to pathogen-derived peptides complexed with polymorphic MHC molecules.
This is called the rule of MHC restriction (1).
Recent years have witnessed a growing appreciation for effector and regulatory functions of
innate-like T cells that are restricted by non-polymorphic,MHC-likemolecules. These includeCD1-
restricted T cells [e.g., natural killer T (NKT) cells] andMR1-restrictedmucosa-associated invariant
T (MAIT) cells, which are the subjects of discussion by leading experts in this Research Topic.
These “unconventional” T cells may directly target infected cells, but are best known for their ability
to swiftly secrete T helper 1 (Th1)-, Th2-, and/or Th17-type cytokines very early in the course of
immune responses. These cytokines in turn modulate the function of numerous cell types including
NK cells, macrophages, dendritic cells, conventional CD4+ and CD8+ T cells and B cells, all of
which play critical roles in innate or adaptive antimicrobial immunity.
CD1molecules appeared around 300million years ago. They display a high degree of conservation
across vertebrates (2). However, considerable inter-species variation exists in terms of the number
of CD1 isoforms expressed. In humans, the CD1 locus encodes five isoforms (i.e., CD1a–e), whereas
rodents express only CD1d (3, 4). With the sole exception of CD1e, CD1 molecules are cell surface
glycoproteins directly participating in lipid Ag presentation to T cells. CD1a–c, which comprise
Group 1 CD1 molecules based on their genomic homology and location, have been a focus of
many studies on host responses to Mycobacterium tuberculosis lipids (5). By contrast, certain self-
lipids and exogenous glycolipids derived from a relatively wide spectrum of pathogens can be
presented to NKT cells by CD1d, which is considered the Group 2 CD1 molecule. Positive selection
of both type I and type II NKT cells in the thymus also requires their interaction with CD1d (6).
These cell types are commonly referred to as invariant NKT (iNKT) and variant NKT (vNKT)
cells, respectively. The discovery of iNKT cell restriction by CD1d and the ability of these cells
to recognize α-galactosylceramide (α-GalCer) (7) prompted the invention of α-GalCer-loaded
CD1d tetramer reagents (8, 9). This can be viewed as a technical breakthrough that has allowed
for accurate identification and functional analysis of iNKT cells in mice and humans. Subsequently,
CD1d tetramers loaded with the myelin-derived glycolipid sulfatide were generated and employed
to identify a substantial fraction of vNKT cells (10). Of note, CD1d-restricted, sulfatide-reactive γδ
T cells have also been described (11, 12). To what extent CD1d-restricted γδ T cells may contribute
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to the resolution of infection is not clearly understood. γδ T cells
are not a major focus of this Topic, but have been introduced and
briefly discussed (13, 14).
iNKT cells are perhaps the most widely studied population of
CD1-restricted T cells. They are relatively infrequent in circula-
tion and in most lymphoid and non-lymphoid tissues. However,
they amass in the mouse liver and in the human omentum (15),
which was dubbed the “abdominal policeman” in 1906 (16). iNKT
cells express NK cell markers along with a canonical TCR consist-
ing of an invariant α chain (Vα14-Jα18 in mice and Vα24-Jα18
in humans) and one of the only fewβ chain choices, namelymouse
Vβ8.2, Vβ2, or Vβ7 and human Vβ11. Positive selection of iNKT
cells is executed by CD1d+CD4+CD8+ thymocytes (6) How-
ever, endogenous CD1d ligand(s) involved in iNKT cells’ thymic
selection have been elusive. KRN7000, an exogenous glycolipid
superagonist of iNKT cells, was first extracted from the sea sponge
Agelas mauritanius in a screen for novel antitumor compounds (7,
17). It has a unique α-GalCer structure and is likely to have orig-
inated from microbes forming a symbiotic relationship with A.
mauritanius. Up until a short time ago, α-GalCer was considered
unnatural to mammals. However, a recent study documented the
presence of α-anomeric glycosylceramides including α-GalCer,
in minute quantities, within mammalian cells, which could serve
as endogenous iNKT cell Ags (18). α-GalCer has been utilized
as a powerful experimental tool in many mouse studies and as
a therapeutic agent in several clinical trials for cancer and viral
diseases (19, 20).
iNKT cells are among first-line emergency responders to
microbes. They quickly accumulate at the sites of infection, injury
or inflammation to aid in mobilization and activation of other
immune cells (21). When infection alters iNKT cell numbers
within a given tissue, it is informative to distinguish between
their recruitment into the tissue and their in situ expansion,
retention or redistribution. Intravital imaging techniques have
permitted the visualization and monitoring of iNKT cells’ behav-
ior in live animals (22, 23). They have revealed, for instance,
that shortly after infection with Borrelia burgdorferi, the causative
agent of Lyme disease, hepatic mouse iNKT cells cease to crawl
along the liver sinusoids, but instead form clusters and establish
firm adhesion with Kupffer cells that have engulfed the blood-
borne spirochete (24). By contrast, within the joints, extravascular
iNKT cells are not stationary and move along blood vessel walls
toward B. burgdorferi (25). This is followed by a direct interaction
with the bacterium and its elimination. There currently exists an
unmet need to track and quantify CD1d-mediated presentation
of pathogen-derived lipids and to investigate the characteristics
of the immunological synapses formed between CD1d+ Ag-
presenting cells (APCs) and iNKT cells during infection. As such,
antibodies to CD1d:glycolipid complexes and soluble iNKT cell
TCR reagents similar to those engineered before (26, 27) may
prove valuable.
Lipid Ags that can be bound to CD1d and directly detected by
iNKT cells are present in a number of pathogenic or commensal
bacteria or protozoan parasites (21, 28, 29). Sphingomonas spp.,
Bacteroides fragilis, B. burgdorferi, Helicobacter pylori, Streptococ-
cus pneumoniae, Streptococcus agalactiae, Leishmania donovani
and Entamoeba histolytica are examples of such microorganisms.
Viruses do not possess lipid ligands for iNKT cell TCRs. How-
ever, infection with some viruses (e.g., dengue virus) leads to
upregulatedCD1d expression consistent with iNKT cell activation
while certain others (e.g., herpesviruses and HIV) downregulate
CD1d to plausibly evade detection by iNKT cells (30, 31). Viral
infection may also induce a shift in host cell lipid profiles, thus
yielding more “antigenic” CD1d ligands (32). The presence of
CD1d:self-lipid complexes is also often required for cytokine-
mediated stimulation of iNKT cells during bacterial and viral
infections. This typically occurs shortly after microbial compo-
nents engage APCs’ Toll-like receptors and induce interleukin
(IL)-12 and IL-18 secretion (13, 33). Finally, iNKT cells can be
activated in a truly CD1d-independent fashion, for instance by a
combination of IL-12 and IL-18 (34) or by group II superantigens
of staphylococcal and streptococcal origin (35, 36).
Both protective and pathogenic roles for iNKT cells have been
reported in infectious disease models. Perhaps evenmore intrigu-
ing, iNKT cell activation could have seemingly contradictory
consequences during infection with different species of the same
pathogen (e.g., Chlamydia spp.) (37). CD1d /  and Jα18 / 
mice have been used extensively to address the contributions
of iNKT cells in infection and immunity. It is noteworthy that
CD1d /  mice are devoid of not only iNKT cells but also vNKT
cells.Moreover, Bedel et al. found that the cellular deficiency of the
original Jα18 /  mice is more broad than initially thought and
that the TCRα repertoire in these mice is shrunk by ~60% (38).
Therefore, except in cases where CD1d /  or Jα18 /  mice have
been reconstituted with iNKT cells as a confirmatory measure,
it may be necessary to revisit earlier findings in these animals.
This is now possible thanks to the recent development of a new
version of Jα18 /  mice with an exclusive iNKT cell deficiency
(39) and a monoclonal antibody that can selectively deplete iNKT
cells in vivo (40).
The role of iNKT cells in infection is dictated, at least partially,
by the pro- versus anti-inflammatory dominance of the cytokines
they produce. For instance, interferon (IFN)-γ-secreting iNKT
cells contribute to the immunopathology of sepsis in the aftermath
of polymicrobial infection, which can be therapeutically attenu-
ated by Th2-skewing glycolipids (41, 42). α-GalCer analogs with
Th1-polarizing properties have also been synthesized and may
be considered as adjuvant candidates in preventative vaccination
(43) and in immunotherapy of infectious diseases that can be
potentially resolved by Th1-dominant responses (44).
vNKT cells, as indicated by their name, have a relatively het-
erogeneous αβ TCR repertoire (45). They are present in mice but
more prominent in humans (14, 46). Unlike iNKT cells, vNKT
cells are unresponsive to α-GalCer. A large sub-population of
vNKT cells react with sulfatide, a self-glycolipid that is abundant
within the central nervous system, liver, kidney, and pancreas.
Several endogenous lipids other than sulfatide have been found
to activate vNKT cells, suggesting that vNKT cells’ recognition
mode can be both specific and somewhat promiscuous. Therefore,
it is not unreasonable to assume that self-lipids released from
infected or damaged cells or even microbial lipids cross-reactive
with self-components may be presented by CD1d to elicit vNKT
cell responses. Potent immunomodulatory cytokines secreted by
vNKT cells mediate protection from or pathology associated with
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infection (14, 46). They also enable vNKT cells to establish cross-
talk with other cell types including but not limited to iNKT cells.
In fact, vNKT and iNKT cells may fulfill opposing functions
during infection, as exemplified by parasitic infections of mice
with Trypanosoma cruzi (47) and Schistosoma mansoni (48). The
limited availability of reliable reagents and tools for vNKT cell
studies constitutes a hurdle in delineating the significance of these
cells in infectious diseases (14). Sulfatide-loaded CD1d tetramers
are not sufficiently stable nor do they stain all vNKT cells. The
advent of 24αβ mice, a transgenic mouse line carrying the rear-
ranged Vα3.2/Vβ9 TCR of a vNKT cell hybridoma, shed light
on certain aspects of vNKT cell biology and development (49).
More recently, Jα18-deficient, IL-4 reporter (Jα18 / 4get) mice
were employed to characterize vNKT cells at a polyclonal level
(50). These mice were found to be responsive to multiple lipid
Ags but not to sulfatide and several phospholipids. Therefore,
until new models become available, we will continue to depend
on these models and on parallel examination of CD1d /  and the
exclusively iNKT cell-deficient version of Jα18 /  mice to study
vNKT cell responses in vivo.
Mucosa-associated invariant T cells are one of the hottest top-
ics in immunology today (51, 52). They express an invariant
TCRα chain (mouse Vα19-Jα33 and human Vα7.2-Jα33) (53,
54), and undergo positive selection by MR1+CD4+CD8+ thy-
mocytes (55). Similar to CD1, MR1 is conserved among diverse
mammalian species. MAIT cells preferentially home to mucosal
tissues – hence their denomination. In human, they circulate at
high frequencies in the blood and also make up ~50% of the
entire hepatic T cell population. MAIT cells are absent from
the peripheral tissues of germ-free mice (55), indicating a strict
requirement for commensalmicroflora inMAIT cell homeostasis.
It has been hypothesized that gut dysbiosis in diseased states
(e.g., type 1 and type 2 diabetes) may change MAIT cell fre-
quencies and functions with metabolic and inflammatory reper-
cussions (29). MAIT cells are rare in wild-type mice, and Vα19
transgenic mice were generated to circumvent the feasibility
limitations of mouse studies. Although several differences have
been reported between mouse and human MAIT cell compart-
ments, recent work suggests that MAIT cells from wild-type mice
resemble their human counterparts more closely than previously
appreciated (56).
MR1 tetramers loaded with reduced 6-hydroxymethyl-8--
ribityllumazine, a MAIT cell Ag, were recently developed to
enable positive identification of mouse and human MAIT cells
(57). The vitamin B2 (riboflavin) biosynthesis pathway supplies
MAIT cell ligands (58–60). Importantly, this pathway operates in
microbes that activate MAIT cells, but not in mammals. How-
ever, host-derived metabolites may potentially form adducts with
intermediates of the riboflavin pathway to generate MAIT cell
neo-antigens (59). MR1 ligands are ubiquitous and harbored by
many bacteria, including commensals. Therefore, how in vivo
MAIT cell responses are controlled remains to be elucidated.
Novel MR1 ligands that do not activate MAIT cells on their own
but compete with bacterial and synthetic MAIT cell stimuli have
been synthesized (60). Thismay inspire the development ofMAIT
cell inhibitors for experimental and therapeutic purposes.
MAIT cells can respond to numerous bacterial strains and
yeasts (51, 52). These includeKlebsiella pneumoniae,Pseudomonas
aeruginosa, Lactobacillus acidophilus, Staphylococcus aureus,
Staphylococcus epidermidis, Candida glabrata, Candida albicans
and Saccharomyces cerevisiae. To test the in vivo significance of
MAIT cells in anti-bacterial immunity, MR1 /  mice have been
utilized and shown to be unable to control infection with K. pneu-
moniae,Mycobacterium bovis bacillus Calmette–Guérin (BCG) or
Francisella tularensis (61–63). Last but not the least, MAIT cells
can be activated by a combination of IL-12 and IL-18 in an MR1-
independent manner (64), which may be important for antiviral
defense.
Innate-like T cells are fast-acting and occupy strategic loca-
tions in the body. Unlike classical MHC molecules, CD1 and
MR1 exhibit limited polymorphism. Therefore, it is only fitting
that CD1 and MR1 ligands are considered by many as attractive
targets for vaccination of genetically diverse human populations.
Despite gaps in our knowledge in this exciting area, which are
outlined by experts in this Topic, the availability of powerful
tools, reagents and models has fueled further interest in CD1-
and MR1-restricted T lymphocytes. α-GalCer has been used in
clinical trials, and Th1- and Th2-promoting, disease/infection-
tailored glycolipid agonists of iNKT cells may find their way into
clinical practice in the future. Furthermore, it is not too far-
fetched to anticipate that once the role of MAIT cells in various
infectious diseases is known, their manipulation by synthetic
ligands and inhibitors can be achieved and potentially used in
immunotherapeutic protocols. The time is ripe for both curiosity-
driven and translational studies on CD1- and MR1-restricted
T cells.
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